埃万妥单抗破局EGFR-TKI耐药困境，在EGFR突变NSCLC治疗领域展现广阔前景。

*以下内容仅供医疗卫生专业人士浏览。

打开网易新闻 查看精彩图片

参考文献：

[1]Westover D, Zugazagoitia J, Cho BC, et al. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol, 2018, 29(suppl_1): i10-i19.

[2] Liao X, He T, Wan X, et al. Clinical management in NSCLC patients with EGFR mutation after osimertinib progression with unknown resistance mechanisms[J]. The Clinical Respiratory Journal, 2024, 18(10): e70025.

[3] Alissa J. C, Lecia V. S & Jessica J. L.Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Nature Reviews Clinical Oncology, 2022.

[4] Cho BC, Lu S et al. MARIPOSA Investigators. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Jun 26.

[5]Passaro A, et al. Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. ESMO Congress 2023, LBA15.

[6]Shirish MG, Byoung CC, Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study. 2024 WCLC. OA.02.03.

[7] Chen ACC, Mok FST, Wong WKY, et al. Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib. Lung Cancer. 2025 Nov 1;210:108808.

[8] ShihJ, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.

[9]S. Popat, K.L. Reckamp, R. Califano, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2. ESMO 2024. Abstract LBA54.

[10] Zhao W, Zhou W, Rong L, et al. Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer. Front Oncol. 2022. 12: 912505.

[11] Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2. 2025 ASCO. Abstract 8639.

审批编码：CP-556189

批准分发日期：12/10/2025

有效期：12/10/2026

*“医学界”力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。